-+ 0.00%
-+ 0.00%
-+ 0.00%

Innate Pharma Highlights Long-Term Clinical Benefit Of Lacutamab In Sézary Syndrome And Mycosis Fungoides At ASCO 2025

Benzinga·05/23/2025 05:41:56
Listen to the news
  • Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented at the ASCO Annual Meeting 2025.
  • Long-term follow-up data from TELLOMAK study confirms the meaningful clinical activity in heavily pretreated SS patients with a global overall response rate (ORR) of 42.9% and an impressive median duration of response of 25.6 months.​
  • Data also confirms meaningful activity in heavily pretreated MF patients with a global ORR of 19.6% and confirms that the anti-tumor activity is observed in all patients (KIR3DL2 ≥1% or < 1% at baseline).
  • These compelling data, in a patient population with multiple prior systemic treatments strongly support the development of lacutamab for MF and SS.